Targeting the Pathways of Human Disease
Regulus Therapeutics Inc. is a biopharmaceutical company aiming to discover, develop, and commercialize microRNA-based therapeutics. Regulus aspires to translate one of the most important new discoveries in biology into a novel approach for innovative medicines and to build the leading microRNA company.
About microRNAs
microRNAs represent a new approach for the treatment of human disease. Most RNAs, such as messenger RNAs (mRNAs), are transcribed from genes and are used to make proteins through the process of translation. microRNAs are believed to be extremely important for human development, normal physiology, and disease.
Therapeutic Focus
Regulus focuses its R&D efforts, initially, in multiple therapeutic areas. Two programs, miR-122 and miR-21, investigate multiple therapeutic opportunities for these two microRNAs. In addition, Regulus' scientist and collaborators are investigating more than 60 microRNAs that are associated with a wide array of diseases.
Intellectual Property
The combination of Isis' and Alnylam's intellectual property (IP) estates for microRNA therapeutics creates what we believe is an unparalleled patent position for pharmaceutical products that target microRNAs. This includes a portfolio of over 900 patents and patent applications, of which over 600 are issued.
